AP/Business Wire

STAT+ | Nuvalent says its ROS1-targeted drug shrank lung tumors in patients who failed other options

The company's drug, zidesamtinib, which targets ROS1, was tested in patients whose tumors had stopped responding to other medications.

By Matthew Herper

Balkanization of vaccine policy raises concerns about vaccine uptake, insurance coverage, experts warn

Firing of CDC vaccine experts leads U.S. toward a balkanized vaccination policy where guidance may depend on personal preference, not scientific expertise.

By Helen Branswell

STAT+ | From boom to bitcoin: A device maker’s surprising pivot amid a Medicare crackdown

Semler Scientific’s artery test QuantaFlo helped insurers like UnitedHealth, Aetna profit from Medicare. Now, amid DOJ scrutiny, company shifts to bitcoin.

By Casey Ross, Bob Herman, Lizzy Lawrence, and Tara Bannow

Jose Luis Magana/AP

STAT+ | Top drug regulator is retiring as FDA departures mount

Jacqueline Corrigan-Curay, who runs a key FDA center, is the latest top official to depart the agency.

By Lizzy Lawrence